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Abstract
Background: The “stem cell theory of cancer” states that a subpopulation of cells with stem cell-like properties
plays a central role in the formation, sustainment, spread, and drug resistant characteristics of malignant tumors.
Recent studies have isolated distinct cell populations from infantile hemangiomas that display properties equivalent
to aberrant progenitor cells, suggesting that, in addition to malignant tumors, benign tumors may also contain a
stem cell-like component.
Methods: In this study, the expression levels of the embryonic stem cell reprogramming factors Oct4, Nanog, Myc,
Sox2, and Klf4 were examined via immunohistochemistry in a panel of 71 benign, borderline, and malignant vascular
tumors including capillary hemangioma, cavernous hemangioma, granulomatous hemangioma, venous hemangioma,
hemangioendothelioma, hemangiopericytoma, and angiosarcoma. Antigenicity for each protein was quantified based
on staining intensity and percentage of tissue positive for each antigen, and subsequently compared to data obtained
from two control tissue sets: 10 vascular tissues and a panel of 58 various malignant sarcomas.
Results and discussion: With the exception of Myc (which was only present in a subset of benign, borderline, and
malignant tumors), Oct4, Nanog, Sox2, and Klf4 were detectable at variable levels across both normal and diseased
tissues. Semi-quantitative evaluation of our immunohistochemical staining revealed that protein expression of Oct4,
Nanog, Myc, and Sox2, but not Klf4, was significantly increased in benign, borderline, and malignant vascular tumors
relative to non-diseased vascular tissue controls. Interestingly, the enhanced levels of Oct4, Nanog, Myc, and Sox2 protein
were approximately equivalent between benign, borderline, and malignant vascular tumors.
Conclusions: These findings provide supporting evidence that enrichment for proteins involved in pluripotency is not
restricted solely to malignant tumors as is suggested by the “stem cell theory of cancer”, but additionally extends to
common benign vascular tumors such as hemangiomas.
Background
The origin of cancer remains unclear, however the “cancer
stem cell theory” postulates that a subpopulation of cancer
cells with stem cell-like properties is responsible for sus-
taining long term tumor growth [1]. In addition, cancer
stem cells give rise to metastases and can act as a reservoir
that potentially leads to relapse after treatment has elimi-
nated all observable signs of the cancer. These cancer
stem cells are believed to be genotypically and/or pheno-
typically related to normal stem cells and share many of
the features of normal stem cells such as self-renewal,
drug resistance, and a proliferative potential to generate a
multi-potent cellular lineage [2, 3]. The core transcription
factors that control “stemness” in embryonic stem cells in-
clude Oct4, Sox2, Nanog, Myc, and Klf4, and the combin-
ation of these factors has been shown to successfully
reprogram differentiated somatic cells into pluripotent
stem cells [4]. There is substantial evidence that cancer
stem cells express these specific markers and their activity
contributes to the oncogenic properties inherent in this
disease [5].
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In addition to malignant tumors, benign prostate, breast,
and angiomyolipoma tumors express various stem cell
markers, suggesting the expression of these markers is not
limited exclusively to malignant tumors [6–9]. It was re-
cently reported that benign infantile hemangiomas, which
are the most common tumors of infancy, express higher
levels of neural crest and stem cell markers at the mRNA
level than dermal microvascular endothelial cells [10], and
within this tumor type resides multiple cellular subpopula-
tions expressing Oct4 and Nanog proteins [11]. Moreover,
it was recently revealed that a clonogenic subpopulation of
cells isolated from cutaneous infantile hemangiomas was
capable of differentiating into endothelial cells, smooth
muscle, or adipocytes [12], suggesting that a stem cell-like
component may drive the etiology of this benign vascular
tumor. These fascinating findings suggest that the “stem-
cell theory of cancer” may serve as a more generalized the-
ory than is currently accepted, and extend to benign
vascular tumors.
Thus, in this study we used immunohistochemical ana-
lysis to examine the expression of the stem cell repro-
gramming factors Oct4, Sox2, Nanog, Myc, and Klf4 in 71
diverse benign and malignant vascular tumors. Our find-
ings surprisingly revealed that, relative to normal endothe-
lial tissues, staining of benign and malignant vascular
tumors demonstrated significantly higher expression of
these stem cell reprogramming factors.
Methods
Immunohistochemistry (IHC)
Blood vessel disease spectrum tissue arrays containing
various vascular tumors and non-diseased controls were
purchased from US Biomax, Inc. (#SO8010). The sarcoma
tissue arrays were purchased from Novus Biologicals
(#NBP2 = 30332). For detection of protein expression, tis-
sue arrays were labeled with anti-Myc (Cat# ab32072;
Abcam), anti-Oct4 (Cat# ab18976; Abcam), anti-Sox2
(Cat# ab97959; Abcam), anti-Klf4 (Cat# ab118961; Abcam),
and anti-Nanog (Cat# ab80892; Abcam) antibodies. Antige-
nicity was detected using Alkaline Phosphatase reactivity
(CellMarque). Positive (primary antibody included) and
negative (primary antibody excluded) controls from human
intestine (Klf4), human testicle (Oct4 and Nanog), rat
brain (Sox2), or human colon cancer (Myc) which have
been reported by the Human Protein Atlas (HPA)
(www.proteinatlas.org) were subjected to immunohis-
tochemistry to validate the specificity of each antibody
tested (Additional file 1: Figure S1). In addition, immuno-
histochemistry for each antigen was performed on adipose
tissue as a negative control, given the HPA revealed no to
very low expression of each protein in this tissue type
(Additional file 1: Figure S1). Immunopositivity was quan-
tified by two metrics: the percentage of tissue with positive
staining (<25 %, 25–50 %, 50–75 %, or >75 %) and the
staining intensity (0 = no staining, + = weak staining, ++ =
moderate staining, +++ = high staining). IHC scores
were determined by multiplying the staining intensity
(0 = 0, + = 1, ++ = 2, +++ = 3) by the percent of tissue
stained (<25 % = 1, 25–50 % = 2, 50–75 % = 3, >75 % = 4)
based on previously described methods [13]. For statistical
analysis, the Mann-Whitney rank sum test was used. Stat-
istical significance was determined if the two-sided P value
of the test was < 0.05. Use of human tissues for research
was approved by TTUHSC board review #11027.
Results
Included in this study were 71 diseased vascular tissue sam-
ples originally collected from human patients, representing
malignant (seven angiosarcomas, two hemangiopericyto-
mas), borderline (six hemangioendothelioma), and benign
(five infantile hemangioma, one capillary hemangioma, 45
cavernous hemangiomas, three granulomatous hemangi-
omas, one venous hemangioma) vascular tumors and one
thrombophlebitis. Known characteristics of patients
grouped according to biopsy classification are reported in
Table 1. As controls, we included two tissue sets in this
analysis: 1) ten non-diseased blood vessel tissues and 2) a
diverse panel of 58 human sarcoma tumors. The non-
diseased blood vessel tissues were chosen to evaluate the
expression of stem cell reprogramming factors in normal
vasculature, while the various sarcomas were selected to
compare the levels of stem cell reprogramming factors in
borderline and malignant vascular sarcomas to that of
other malignant mesenchymal tumors.
IHC staining for the stem cell reprogramming factors
Oct4, Nanog, Myc, Klf4, and Sox2 was performed in the
vascular tumor samples as well as the two control tissue
sets. Representative images of each staining are depicted
in Figs. 1, 2, 3, 4 and 5. With the exception of Myc, each
of these proteins was detectable at variable levels across
non-diseased vascular tissues, ranging from 50 % of nor-
mal tissues displaying Nanog and Klf4 immunoreactivity
to 90 % of normal tissues displaying Oct4 immunoreac-
tivity (Table 2). Expression of these “stem cell regulators”
in non-diseased adult tissue is not surprising given that
the HPA reports detection of Oct4, Nanog, Klf4, and Sox2
in approximately 70, 11, 29, and 51 % of normal human tis-
sues, respectively. Though HPA reports Myc expression in
Table 1 Vascular tumor and control patient characteristics
Variable Overall Malignant Borderline Benign Normal
# patient
samples
81 9 6 56 10
Age [mean
years (s.d.)]
41 ± 17 53 ± 19 36 ± 15 40 ± 17 34 ± 14
Age [median
years (range)]
42 (80) 53 (64) 35 (44) 42 (71) 32 (44)
Sex 42 F, 39 M 4 F, 5 M 6 F, 0 M 27 F, 29 M 5 F, 5 M
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56 % of normal human tissues, we did not detect this pro-
tein in any non-diseased vascular tissues tested in this ana-
lysis. While immunostaining for these stem cell regulators
was observed in non-diseased vasculature, the IHC score
for these tissues was relatively low given that staining inten-
sity for each stem cell marker was weak to moderate and
often occurred in a very small fraction (<25 %) of the cells
comprising the tissue (Fig. 6, Additional file 2: Table S1).
In contrast to the non-diseased vascular rich tissue con-
trols, benign vascular tumors and the single thrombophle-
bitis sample exhibited significantly increased staining (in
both intensity and percentage of positive tissue) for Oct4,
Nanog, Myc, and Sox2, with no statistically significant in-
crease in antigenicity for Klf4 (Fig. 6, Additional file 2:
Table S1). It is worth noting that unlike the absence of
Myc expression in normal vasculature, 46 % of the benign
tumors tested were positive for Myc protein. The data ob-
tained from malignant and borderline vascular tumors
were remarkably similar to that demonstrated from the
benign vascular tumors. Malignant and borderline vascu-
lar sarcomas displayed 100 % immunoreactivity for Oct4,
Nanog, and Sox2, while Myc protein was present in 50 %
of malignant and borderline vascular tumors (Table 2).
The IHC scores for all proteins tested except Klf4 were
significantly increased in the malignant and borderline
vascular tumors relative to the non-diseased controls, and
were surprisingly very similar to the levels observed in be-
nign vascular tumors. The elevated IHC scores observed
for malignant and borderline vascular tumors correlated
to the results obtained in a diverse panel of malignant sar-
coma cells, revealing immunoreactivity for Oct4, Nanog,
and Sox2 in 100 % of various sarcoma tissues and 72 %
for Myc and Kfl4 (Additional file 2: Table S2). While Klf4
protein expression was not significantly different between
any of the vascular tumors or vascular tissue controls, this
protein did show a significantly increased mean IHC score
Fig. 1 Representative images of Oct4 staining in normal and vascular
tumor tissues. Immunopositivity for Oct4 protein is represented by
brown staining. Positive control (left panel) = human testicle; negative
control (right panel) = human testicle with no added primary antibody.
400× total magnification for each image
Fig. 2 Representative images of Nanog staining in normal and vascular
tumor tissues. Immunopositivity for Nanog protein is represented by
brown staining. Positive control (left panel) = human testicle; negative
control (right panel) = human testicle with no added primary antibody.
400× total magnification for each image
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in the sarcoma tissue control set (Fig. 6, Additional file 2:
Table S2). The expression of Oct4, Nanog, Myc, Sox2, and
Klf4 in the current study correlated well with data re-
ported in the HPA which reveals expression of Oct4 in
88 % of cancers, Sox2 in 88 % of cancers, Myc in
78 % of cancers, Klf4 in 28 % of cancers, and Nanog
in 7 % of cancers.
Discussion
This study directly stems from the results of a handful
of recent publications which suggest that the benign
vascular tumor, infantile hemangioma, harbors a sub-
population of stem cell-like progenitor cells. mRNA and
protein expression of neural crest and stem cell markers
was previously confirmed in a panel of hemangioma sam-
ples, revealing variable expression levels for Oct4, Myc,
Sox2, and Nanog [10, 11]. These publications suggest that
infantile hemangiomas may contain cells that are capable
of differentiating into all three embryonic germ layers and
additionally point to a possible mechanism of clonality in
these tumors. Indeed, implantation of isolated CD133+
stem cell populations from infantile hemangiomas pro-
duce hemangioma-like tumors in xenograft animal models
[14], however Oct4 and Nanog positive subpopulations
from infantile hemangiomas failed to form teratomas in
SCID/NOD mice [11], a hallmark of embryonic stem cell-
derived tumors [15], suggesting they do not function like
true embryonic stem cells. Substantial lines of evidence
controversially suggest that congenital and infantile hem-
angiomas originate from metastatic spread of placental
chorangiomas [16–20], creating a possibility in which the
etiology of some childhood hemangiomas (at least in their
earliest stages) may be more similar to metastatic tumors
than benign tumors. Thus, our observations that both in-
fantile hemangiomas and malignant vascular tumors such
as angiosarcomas and hemangiopericytomas expressed
stem cell reprogramming factors at significantly increased
Fig. 3 Representative images of Myc staining in normal and vascular
tumor tissues. Immunopositivity for Myc protein is represented by
brown staining. Positive control (left panel) = human colon cancer;
negative control (right panel) = human colon cancer with no added
primary antibody. 400× total magnification for each image
Fig. 4 Representative images of Sox2 staining in normal and vascular
tumor tissues. Immunopositivity for Sox2 protein is represented by
brown staining. Positive control (left panel) = rat brain; negative control
(right panel) = rat brain with no added primary antibody. 400× total
magnification for each image
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and relatively similar levels compared to non-diseased vas-
cular tissue, is not entirely surprising.
In contrast, our highly novel observations that other
benign vascular tumors such as adult capillary, cavern-
ous, granulomatous, and venous hemangiomas as well as
the single thrombophlebitis sample displayed expression
of Oct4, Nanog, Myc, and Sox2 in similarly elevated
rates and intensities as seen in malignant sarcomas was
quite surprising. These benign tumors often occur in the
third to fourth decade of life, thus their origin cannot be
attributed easily to distal neoplasms as arguably may occur
in infantile hemangiomas. These expression patterns in di-
verse benign vascular tumors are intriguing given that the
presence of “stemness” proteins in malignant tumors is
well established in the literature and forms the basis for
the “stem cell theory of cancer”; however our data provide
strong evidence that these proteins could potentially con-
tribute to the formation and/or properties associated with
a diverse array of benign vascular tumors. Though more
studies must be performed for definitive arguments either
way, it is possible that the “stem cell theory of cancer” is
too narrowly defined in its current state and may need to
be broadened to include benign neoplasms. This subject
should be treaded lightly and with careful future evalu-
ation as, while Oct4 has been shown to maintain pluripo-
tency during early embryogenesis, its role as a pure stem
cell marker has been questioned given that it is also
expressed in differentiated cells [21, 22]. Nanog expression
has been reported in E18 stage rat myocardial tissues, and
is detectable in post-natal stages up to 30 days after birth
and after acute myocardial infarction [23, 24].
Compared to the abundance of research performed in
carcinomas and hematopoietic cancers, relatively min-
imal work has been reported evaluating the presence of
stem cells as driving components in malignant mesenchy-
mal tumors, and much of these efforts have focused exclu-
sively on pediatric bone and musculoskeletal sarcomas
[25–27]. For instance, osteosarcomas and Ewing’s sarcomas
express Oct4 and Nanog [25, 28, 29] and rhabdomyosarco-
mas express Oct4, Nanog, and Sox2 [30]. Moreover, the
EWS-FLI1 fusion gene, present in nearly 85 % of Ewing’s
sarcomas, induces the expression of Oct4, Nanog, and
Sox2 in human pediatric mesenchymal stem cells but
not their adult counterparts [31]. Though drug resistant
progenitor-like cell populations have been reported for
angiosarcomas [32, 33], only expression of Myc as an em-
bryonic stem cell marker has been thoroughly examined in
malignant vascular tumors [34]. It has been reported that
Myc gene amplification and overexpression occurs in post-
irradiation induced angiosarcomas, but not in primary cu-
taneous angiosarcomas or in other radiation-associated
vascular proliferations [35, 36]; however several other stud-
ies provide evidence that Myc amplification and overex-
pression is not a definitive marker of radiation-induced
tumorigenesis in angiosarcomas [37–39]. Our data add-
itionally demonstrates that Oct4, Nanog, Sox2, Klf4, and
Myc are widely expressed at high levels across a wide var-
iety of sarcomas and benign vascular tumors at elevated
levels. While the data reported in this study in no way indi-
cate that the cells expressing these markers are cancer
stem cells (which generally make up single digit or less per-
centages of the total cancer cell population in a tumor), the
Fig. 5 Representastive images of Klf4 staining in normal and vascular
tumor tissues. Immunopositivity for Klf4 protein is represented by
brown staining. Positive control (left panel) = human intestine; negative
control (right panel) = human intestine with no added primary
antibody. 400× total magnification for each image
Table 2 Percentage of tumors with positive antigenicity for
embryonic stem cell reprogramming factors
Protein Normal Benign Borderline Malignant Various Sarcomas
Oct4 90 % 100 % 100 % 100 % 100 %
Nanog 50 % 98 % 100 % 100 % 100 %
Myc 0 % 46 % 50 % 50 % 72 %
Sox2 60 % 98 % 100 % 100 % 100 %
Klf4 50 % 59 % 67 % 63 % 72 %
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statistically significant increases in Oct4, Nanog, Sox2, and
Myc expression in benign and malignant tumors relative to
normal tissues provides correlative support that overex-
pression of these proteins could contribute to their overall
tumorigenic properties.
Conclusion
In conclusion, the data presented in this study demon-
strate that the protein expression of embryonic stem cell
reprogramming factors is enriched in benign, borderline,
and malignant vascular tumors. This finding could trans-
late to future therapeutic targeting of tumor cell popula-
tions that express embryonic stem cell reprogramming
factors to disrupt tumor cell clonality, long term growth,
and drug resistance.
Additional files
Additional file 1: Figure S1. Positive and negative staining controls. For
each indicated antigen detected by immunohistochemistry, three controls
were performed. The Negative Control column represents images acquired
following immunohistochemistry against the indicated antigen on adipocyte
tissue, which has been shown by the HPA to express no to low levels of
each protein. The No Primary Antibody column represents images acquired
following immunohistochemistry using no primary antibody on tissues as
indicated in the Materials and Methods section to demonstrate that the
detection system was no causing background staining on the
samples. The Positive Control column represents images acquired
from immunohistochemistry using the indicated antibody on tissues
as indicated in the Materials and Methods section that are known to
strongly express each antigen. (DOC 488 kb)
Additional file 2: Table S1. Immunopositivity for stem cell
reprogramming factors in malignant and benign vascular tumors.
Table S2. Immunopositivity for stem cell reprogramming factors in
a panel of diverse sarcomas. (DOC 214 kb)
Fig. 6 Antigenicity for embryonic stem cell reprogramming factors in normal tissue and vascular tumors. Box and whisker plots depicting the IHC scores
for Oct4, Nanog, Myc, Sox2, and Klf4 in normal vasculature, benign, borderline or malignant vascular tumors, or across a panel of various sarcomas. The
Mann-Whitney rank sum test was used to determine statistical significance. Significance was determined if the two-sided P value of the test was < 0.05.
Asterisks indicate level of significance relative to normal vasculature (* p < 0.05, ** p < 0.05, *** p < 0.005, **** p< 0.0005)
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